Multicenter Study

. 2017 Feb;143(2):329-335.

doi: 10.1007/s00432-016-2292-3. Epub 2016 Oct 22.

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Zai-Shang Li^{1

2

3}, Chuang-Zhong Deng^{1

2

3}, Kai Yao^{1

2

3}, Yong Tang⁴, Nan Liu⁵, Peng Chen⁶, Bin Wang⁷, Xiang Li⁸, Xiao-Feng Chen⁹, Hong Liao¹⁰, Qi-Wu Mi¹¹, Yong-Hong Lei¹², Qi Zhao^{2

3

13}, Pei-Zhen Zhao¹⁴, Xue-Ying Li^{2

3

15}, Jie-Ping Chen^{1

2

3}, Qiang-Hua Zhou^{1

2

3}, Zi-Ke Qin^{1

2

3}, Zhuo-Wei Liu^{1

2

3}, Yong-Hong Li^{1

2

3}, Yun-Lin Ye^{1

2

3}, Hua Tu^{1

2

3}, Zi-Jun Zou⁷, Xing Bi⁶, Feng Yang⁶, Ying-Ming Xiao¹⁰, Jing Li⁷, Xiang-Tian Lin¹⁶, Wei-Cong Liang¹⁶, Hui Han^{17

18

19}, Fang-Jian Zhou^{20

21

22}

Affiliations

¹ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
² State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China.
³ Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China.
⁴ Department of Urology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, People's Republic of China.
⁵ Department of Urology Oncological Surgery, Chongqing Cancer Hospital and Institute and Cancer Center, Chongqing, China.
⁶ Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Ürümchi, People's Republic of China.
⁷ Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
⁸ Department of Urology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
⁹ Department of Urology, The First People's Hospital of Chenzhou, Chenzhou, People's Republic of China.
¹⁰ Department of Urology, Sichuan Cancer Hospital, Chengdu, People's Republic of China.
¹¹ Department of Urology, Dong Guan People's Hospital, Dongguan, People's Republic of China.
¹² Department of Urology, Yunnan Provincial Tumor Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China.
¹³ School of Life Science, Sun Yat-Sen UniversitySchool of Life Science, Guangzhou, People's Republic of China.
¹⁴ Guangdong Provincial Center for Skin Disease and STI Control, Guangzhou, People's Republic of China.
¹⁵ Department of Medical Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, People's Republic of China.
¹⁶ Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, People's Republic of China.
¹⁷ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. hanhui@sycucc.org.cn.
¹⁸ State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China. hanhui@sycucc.org.cn.
¹⁹ Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China. hanhui@sycucc.org.cn.
²⁰ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. Zhoufj@sycucc.org.cn.
²¹ State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China. Zhoufj@sycucc.org.cn.
²² Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China. Zhoufj@sycucc.org.cn.

PMID: 27771796
PMCID: PMC11819431
DOI: 10.1007/s00432-016-2292-3

Multicenter Study

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Zai-Shang Li et al. J Cancer Res Clin Oncol. 2017 Feb.

. 2017 Feb;143(2):329-335.

doi: 10.1007/s00432-016-2292-3. Epub 2016 Oct 22.

Authors

Affiliations

¹ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
² State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China.
³ Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China.
⁴ Department of Urology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, People's Republic of China.
⁵ Department of Urology Oncological Surgery, Chongqing Cancer Hospital and Institute and Cancer Center, Chongqing, China.
⁶ Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Ürümchi, People's Republic of China.
⁷ Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
⁸ Department of Urology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
⁹ Department of Urology, The First People's Hospital of Chenzhou, Chenzhou, People's Republic of China.
¹⁰ Department of Urology, Sichuan Cancer Hospital, Chengdu, People's Republic of China.
¹¹ Department of Urology, Dong Guan People's Hospital, Dongguan, People's Republic of China.
¹² Department of Urology, Yunnan Provincial Tumor Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China.
¹³ School of Life Science, Sun Yat-Sen UniversitySchool of Life Science, Guangzhou, People's Republic of China.
¹⁴ Guangdong Provincial Center for Skin Disease and STI Control, Guangzhou, People's Republic of China.
¹⁵ Department of Medical Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, People's Republic of China.
¹⁶ Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, People's Republic of China.
¹⁷ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. hanhui@sycucc.org.cn.
¹⁸ State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China. hanhui@sycucc.org.cn.
¹⁹ Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China. hanhui@sycucc.org.cn.
²⁰ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. Zhoufj@sycucc.org.cn.
²¹ State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China. Zhoufj@sycucc.org.cn.
²² Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China. Zhoufj@sycucc.org.cn.

PMID: 27771796
PMCID: PMC11819431
DOI: 10.1007/s00432-016-2292-3

Abstract

Background: Current guidelines recommend pelvic lymphadenectomy (PLND) for patients with pelvic lymph node metastasis and special state. However, these data and recommendations do not distinguish the role of PLND in different patient groups and confirm the final benefits. The aim of this study was to confirm the efficacy of pelvic lymphadenectomy (PLND) for the different groups of patients.

Methods: Data obtained from 7 centers were retrospectively analyzed. Of the patients, 190 pN2-3 penile carcinoma patients confirmed by bilateral inguinal lymph node excision were included in this study. Sixty-nine and 121 of these patients did and did not undergo bilateral PLND, respectively. The baseline differences from the patients were matched by propensity score analysis.

Results: In this study, the Kaplan-Meier estimated disease-specific survival (DSS) was not significantly different between the PLND and no-PLND groups (P = 0.796). According to the propensity score matching for T stage, N stage, grade, adjuvant therapies, and lymph node stage (number of inguinal lymph node metastasis and extranodal extension), 48 patients were selected for each group. Among the pN2 patients, the PLND group showed higher DSS rates than the no-surgery group (P = 0.030). However, even after matching, survival did not differ between the PLND and no-PLND patients among all patients (P = 0.609) and pN3 patients (P = 0.417) with comparable DSS.

Conclusion: Bilateral PLND may improve survival in pN2 patients. Men with pN3 may not benefit from bilateral PLND.

Keywords: Lymph node excision; Mortality; Neoplasm metastasis; Penile neoplasms.

PubMed Disclaimer

Conflict of interest statement

All of the authors declare that they have no conflict of interest.

Figures

**Fig. 1**
Flow chart of the study population. *PLND* pelvic lymphadenectomy; *PSCC* penile squamous cell carcinoma

**Fig. 2**
Kaplan–Meier curve for DSS between the PLND and no-PLND groups. a All study patients; b patients selected in the propensity model; c pN2 patients selected in the propensity model; d pN3 patients selected in the propensity model

See this image and copyright information in PMC

Cited by

Pelvic lymph node dissection alone versus adjuvant radiotherapy in node positive penile cancer: A systematic review.
Naushad N, Deb AA, Agag AA, Serag HA, Sangar VK. Naushad N, et al. Indian J Urol. 2022 Apr-Jun;38(2):91-98. doi: 10.4103/iju.iju_453_21. Epub 2022 Apr 1. Indian J Urol. 2022. PMID: 35400869 Free PMC article. Review.
Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report.
Hu L, Shan X, Han D, Guo Z, Wang H, Xiao Z. Hu L, et al. Onco Targets Ther. 2021 Sep 22;14:4891-4896. doi: 10.2147/OTT.S319932. eCollection 2021. Onco Targets Ther. 2021. PMID: 34588783 Free PMC article.
Pelvic Lymph Node Dissection in Penile Cancer With Inguinal Lymph Node Extranodal Extension: A Multicenter Experience.
Li ZS, Han H, Deng CZ, Li YH, Wu C, Chen P, Liu ZW, Qin ZK, Zhou FJ. Li ZS, et al. Front Surg. 2021 Jun 15;8:644273. doi: 10.3389/fsurg.2021.644273. eCollection 2021. Front Surg. 2021. PMID: 34211998 Free PMC article.
Proposal of a Subclassification of pN3 in Squamous Cell Carcinoma of the Penis.
Patel KN, Sharma M, Yalla P, Aaron J, Salunke A, Puj K, Warikoo V, Pal M, Bakshi G, Pandya SJ. Patel KN, et al. Ann Surg Oncol. 2025 Feb;32(2):1346-1353. doi: 10.1245/s10434-024-16442-y. Epub 2024 Nov 12. Ann Surg Oncol. 2025. PMID: 39532758
Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?
Suarez-Ibarrola R, Basulto-Martinez M, Sigle A, Abufaraj M, Gratzke C, Miernik A. Suarez-Ibarrola R, et al. J Clin Med. 2021 Feb 13;10(4):754. doi: 10.3390/jcm10040754. J Clin Med. 2021. PMID: 33668548 Free PMC article. Review.

See all "Cited by" articles

References

1. Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D et al (2010) The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology 75:1431–1435 - PMC - PubMed
1. Clark PE (2015) NCCN clinical practice guidelines in oncology (NCCN Guidelines) penile cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#penile
1. D’Agostino RJ (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281 - PubMed
1. Di Lorenzo G, Buonerba C, Federico P, Perdona S, Aieta M, Rescigno P et al (2012) Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 110:E661–E666 - PubMed
1. Djajadiningrat RS, van Werkhoven E, Horenblas S (2015) Prophylactic pelvic lymph node dissection in patients with penile cancer. J Urol 193:1976–1980 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Affiliations

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources